RxDoctor Payments Data

Taylore Chanillo, NP

Family · Bridgewater, NJNPI 1982352530

Payments from drug & device makers

$4,488in general payments, 2019–2025

Across 153 payments — averaging $29.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • TG Therapeutics, Inc.$787
  • Bristol Myers Squibb$473
  • E.r. Squibb & Sons, L.L.C.$432
  • Novartis$417
  • Biogen$335
  • Amgen$324
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,42599%
  • Education$631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,488 in reported general payments places this provider in the 90th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$103,412
Medicare patients
104
Services billed
1,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$12,270
Tresiba Flextouch U-200Insulin Degludec18$11,700
Fentanyl22$1,553
Methenamine Hippurate17$593
Gabapentin34$547
Sevelamer Carbonate11$534
Metformin Hcl ErMetformin Hcl18$377
Hydralazine Hcl13$375
Atorvastatin Calcium39$342
Tramadol Hcl35$328
Potassium Chloride13$318
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$318
Levothyroxine Sodium20$271
Tizanidine Hcl12$201
Meloxicam23$185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$12,27034 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,692 family providers in New Jersey.

Other family in Bridgewater

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →